FDA Approves TOPAMAX — Janssen Pharmaceuticals, Inc.

# FDA Approves Janssen Pharmaceuticals' TOPAMAX (Topiramate) for Oral Use Janssen Pharmaceuticals, Inc. received FDA approval for TOPAMAX (topiramate) oral formulation on October 26, 1998, marking a significant addition to the company's neurology portfolio and positioning it to capture market share in the anticonvulsant and migraine prevention segments. The approval establishes a foundation for Janssen to expand TOPAMAX's commercial reach across multiple therapeutic indications and establish the drug as a key revenue driver in the antiepi